Details of the Drug Combinations

General Information of This Drug (ID: DM1YVZT)

• Drug Name: Rituximab (DM1YVZT)

Indication

Central nervous system non-hodgkin lymphoma; ICD 11: N.A.; Status: Approved [1]; Eosinophilic granulomatosis with polyangiitis; ICD 11: 4A44.A2; Status: Approved [2]; Hepatosplenic T-cell lymphoma; ICD 11: N.A.; Status: Approved [3]; Idiopathic thrombocytopenic purpura; ICD 11: 3B64.10; Status: Approved [4]; Large granular lymphocytic leukemia; ICD 11: 2A90.1; Status: Approved [5]; Leukemia; ICD 11: N.A.; Status: Approved [6]; Lupus nephritis; ICD 11: 4A40.0Y; Status: Approved [7]; Lymphoproliferative syndrome; ICD 11: N.A.; Status: Approved [8]; Lymphosarcoma; ICD 11: N.A.; Status: Approved [9]; MALT lymphoma; ICD 11: N.A.; Status: Approved [10]; Nodal marginal zone lymphoma; ICD 11: 2A85.0; Status: Approved [11]; Non-hodgkin lymphoma; ICD 11: 2B33.5; Status: Approved [12]; Primary cutaneous peripheral T-cell lymphoma not otherwise specified; ICD 11: N.A.; Status: Approved [13]; Prolymphocytic leukaemia; ICD 11: 2A82.1; Status: Approved [14]; Recurrent adult burkitt lymphoma; ICD 11: 2A85.6; Status: Approved [15]; Small intestine lymphoma; ICD 11: N.A.; Status: Approved [16]; Small lymphocytic lymphoma; ICD 11: 2A82.0; Status: Approved [17]; Splenic marginal zone lymphoma; ICD 11: N.A.; Status: Approved [18]; Testicular lymphoma; ICD 11: N.A.; Status: Approved [19]; Thrombotic thrombocytopenic purpura; ICD 11: 3B64.14; Status: Approved [20]; Waldenstrom macroglobulinemia; ICD 11: 2A85.4; Status: Approved [21]; Pemphigus vulgaris; ICD 11: EB40; Status: Phase 3 [22]; Haematological malignancy; ICD 11: 2B33.Y; Status: Phase 1 [23]; B-cell neoplasm; ICD 11: N.A.; Status: Investigative [24]

• Drug Type: Antibody

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Rituximab + Iboctadekin	DC38HON	Iboctadekin	Follicular lymphoma; Non-hodgkin lymphoma; Atrial fibrillation	[25]
Rituximab + ACTR087	DCKW0JR	ACTR087	B-cell lymphoma	[26]
Rituximab + Bevacizumab	DCZKJEZ	Bevacizumab	Non-hodgkin lymphoma; Lymphoma	[25]

References

• [1] How we treat primary central nervous system lymphoma. ESMO Open. 2021 Aug;6(4):100213.
• [2] Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019 Oct;68(4):430-436.
• [3] Coexistent hairy cell leukaemia and hepatosplenic T-cell lymphoma: a case report. Diagn Pathol. 2014 Mar 12;9:58.
• [4] Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease. Rom J Intern Med. 2019 Dec 1;57(4):273-283.
• [5] Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. Semin Arthritis Rheum. 2020 Oct;50(5):1109-1113.
• [6] Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 1;106(7):1569-80.
• [7] 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723.
• [8] Autoimmune lymphoproliferative syndrome: A disorder of immune dysregulation. Autoimmun Rev. 2023 Nov;22(11):103442.
• [9] Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18(4):465-71.
• [10] Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. J Clin Med. 2022 Dec 23;12(1):120.
• [11] Nodal marginal zone lymphoma. Leuk Lymphoma. 2014 Jun;55(6):1240-50.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [13] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [14] B and T cell prolymphocytic leukaemia. Best Pract Res Clin Haematol. 2019 Sep;32(3):217-228.
• [15] Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy. Leuk Lymphoma. 2023 Mar;64(3):586-596.
• [16] Metachronous primary cancer of the tongue and malignant lymphoma of the small intestine: A case report. Medicine (Baltimore). 2021 Feb 19;100(7):e24806.
• [17] Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022 Aug;23(8):1031-1043.
• [18] Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol. 2017 Mar-Jun;30(1-2):139-148.
• [19] First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011 Jul 10;29(20):2766-72.
• [20] Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med. 2021 Feb 2;10(3):536.
• [21] Waldenstr?m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023 Feb;98(2):348-358.
• [22] ClinicalTrials.gov (NCT02383589) A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris. U.S. National Institutes of Health.
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6780).
• [24] Diffuse Large B-Cell Lymphoma and Related Entities. Dtsch Arztebl Int. 2023 Apr 28;120(17):289-296.
• [25] FDA Drug Development and Drug Interactions
• [26] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)